

# A DEFIBRILLATOR IS INDICATED : SHOULD WE RESYNCHRONISE ?



Michel CHAUVIN  
DIU 2007

**M.CHAUVIN**



# A DEFIBRILLATOR IS INDICATED : SHOULD WE RESYNCHRONISE ?


**RESYNCHRONIZATION**



**HEART FAILURE PATIENT  
+ CRITERIA**

Michel CHAUVIN  
DIU 2007

**I.C.D. INDICATED**



**PROBABILITY  
OF SUDDEN  
CARDIAC DEATH**


**RESYNCHRONIZATION**



**HEART FAILURE PATIENT  
+ CRITERIA**

Michel CHAUVIN  
DIU 2007

**I.C.D. INDICATED**



**PROBABILITY  
OF SUDDEN  
CARDIAC DEATH**

**RESYNCHRONIZATION**

**I.C.D. INDICATED**


**PROBABILITY  
OF SUDDEN  
CARDIAC DEATH**

**HEART FAILURE PATIENT  
+ CRITERIA**

# **Cardiac Resynchronization Therapy for the Treatment of Heart Failure in Patients with Intraventricular Conduction Delay and Malignant Ventricular Tachyarrhythmias**


***SL Higgins et al JACC 2003; 42 : 1454-9***


# PHASE I



INVESTIGATOR  
DISCRETION

# PHASE II





**The CRT improved functional status in patients indicated for an ICD who also have symptomatic HF and intraventricular conduction delay**



# **A DEFIBRILLATOR IS INDICATED : SHOULD WE RESYNCHRONISE ?**

**YES , WHEN AN I.C.D. IS INDICATED  
IN A PATIENT  
WITH « OFFICIAL » CRITERIA  
OF RESYNCHRONIZATION**

# A DEFIBRILLATOR IS INDICATED : SHOULD WE RESYNCHRONISE ...



**A DEFIBRILLATOR IS INDICATED :  
SHOULD WE RESYNCHRONISE ...**

**... WHEN A PATIENT  
HAS ANY OF THE « OFFICIAL » CRITERIA  
FOR A RESYNCHRONIZATION ?**

**NYHA CLASSES I AND II**

# **A DEFIBRILLATOR IS INDICATED : SHOULD WE RESYNCHRONISE ...**

**THE NATURAL HISTORY OF  
MILD SYMPTOMATIC HEART FAILURE**

**DOES RESYNCHRONIZATION PREVENT  
DISEASE WORSENING ?**

**DOES RESYNCHRONIZATION PREVENT REMODELING ?**


# Natural History of Asymptomatic Left Ventricular Systolic Dysfunction (ALVD) in the Community

Michel CHAUVIN  
DIU 2007


Thomas J. Wang, et al  
*Circulation*. 2003;108:977

# Natural History of ALVD

- FRAMINGHAM STUDY
- MILD ALVD (  $0.4 \leq \text{LVEF} \leq 0.5$  )
- MODER./SEVERE ALVD (  $\text{LVEF} < 0.4$  )
- NO HISTORY OF C.H.F.
- 12 YEARS FOLLOW UP



**KAPLAN-MEIER CURVES FOR SURVIVAL**



**KAPLAN-MEIER CURVES FOR SURVIVAL FREE OF CHF**

Michel CHAUVIN  
DIU 2007

# CONCLUSIONS

- **Individuals with ALVD in the community are at high risk of CHF and death, even when only mild impairment of EF is present.**
- **Additional studies are needed to define optimal therapy for mild ALVD.**



# Causes and Consequences of Heart Failure After Prophylactic Implantation of a Defibrillator in the Multicenter Automatic Defibrillator Implantation Trial II

**MADIT II Investigators**

***I. Goldenberg et al***


***Circulation 2006; 113: 2810-17***

**TABLE 1. Clinical Characteristics of Patients in the Conventional-Therapy Group and in the Defibrillator Group by Device Type**


	Conventional (n=482)	Defibrillator	
		Single Chamber (n=402)	Dual Chamber (n=313)
Age $\geq 65$ y, %	53	47	61§
Female sex, %	15	16	14
NYHA functional class $\geq 2$ , %*	60	61	72§
I	40	39	28§
II	34	35	37
III	22	22	30
IV	4	4	5

**MADIT II Investigators**

***I. Goldenberg et al Circulation 2006; 113: 2810-17***




## KAPLAN-MEIER ESTIMATES OF ALL-CAUSE MORTALITY (A)



PATIENTS AT RISK

ICD 736	491 (0.09)	263 (0.15)	102 (0.22)
Conventional 482	314 (0.09)	159 (0.20)	55 (0.30)



PATIENTS AT RISK


ICD 736	403 (0.24)	208 (0.33)	74 (0.42)
Conventional 482	272 (0.22)	137 (0.34)	49 (0.43)

**KAPLAN-MEIER ESTIMATES OF ALL-CAUSE MORTALITY (A)**

**(B) ALL-CAUSE MORTALITY OR FIRST HOSPITALIZATION FOR HF**


**(B) ALL-CAUSE MORTALITY OR FIRST HOSPITALIZATION FOR HF**

**(C) FIRST HOSPITALIZATION FOR HF WITH CENSORING ON DEATH**



PATIENTS AT RISK

ICD	736	403 (0.24)	208 (0.33)	74 (0.42)
Conventional	482	272 (0.22)	137 (0.34)	49 (0.43)



PATIENTS AT RISK

ICD	736	403 (0.19)	208 (0.26)	74 (0.33)
Conventional	482	272 (0.15)	137 (0.21)	49 (0.25)

# MADIT II CONCLUSION

- **ICD THERAPY TRANSFORMS SUDDEN DEATH RISK TO A SUBSEQUENT HF RISK.**
- **THESE FINDINGS SHOULD DIRECT MORE ATTENTION TO THE PREVENTION OF HF IN PATIENTS WHO RECEIVE AN ICD**

**Multicenter InSync Randomized Clinical  
Evaluation (MIRACLE) Study Group.  
Effect of Cardiac Resynchronization  
Therapy on Left Ventricular Size and  
Function in Chronic Heart Failure**

**SJ SUTTON et al**

***Circulation 2003; 107 : 1985-90***

# STUDY ENDPOINTS

- **Primary Efficacy:**
  - NYHA Functional Class
  - Quality of life (Minnesota Living with Heart Failure)
  - 6-minute Walk Distance
- **Secondary Efficacy Included:**
  - Peak  $VO_2$ , Exercise Time, LVEF, LVEDD, MR, QRS Duration, Clinical Composite Response
- **Other Protocol Specified Endpoints:**
  - Death or Worsening Heart Failure (Safety)
  - # Days Spent in Hospital (Health Care Utilization)



# PATIENTS CHARACTERISTICS


	<b>Control N=225</b>	<b>CRT N=228</b>
<b>Age (years)</b>	<b>65 ± 11</b>	<b>64 ± 11</b>
<b>Gender (% male)</b>	<b>68%</b>	<b>68%</b>
<b>Heart Failure Etiology (% ischemic)</b>	<b>58%</b>	<b>50%</b>
<b>NYHA (% Class III)</b>	<b>91%</b>	<b>90%</b>
<b>QRS duration (ms)</b>	<b>165 ± 20</b>	<b>167 ± 21</b>
<b>LVEF (%)</b>	<b>22 ± 6</b>	<b>22 ± 6</b>
<b>LVEDD, mm</b>	<b>69 ± 10</b>	<b>70 ± 10</b>

# PATIENTS CHARACTERISTICS


	Control N=225	CRT N=228
Age (years)	65 ± 11	64 ± 11
Gender (% male)	68%	68%
Heart Failure Etiology (% ischemic)	58%	50%
<b>NYHA (% Class III)</b>	<b>91%</b>	<b>90%</b>
QRS duration (ms)	165 ± 20	167 ± 21
LVEF (%)	22 ± 6	22 ± 6
LVEDD, mm	69 ± 10	70 ± 10

# RESULTS


**Distance Walked in 6 Minutes**  
Change from Baseline\*






**CRT IMPROVES NYHA FUNCTIONAL CLASS**



**Minnesota Living with Heart Failure Questionnaire**  
Change from Baseline\*






**SJ SUTTON et al**  
*Circulation* 2003; 107 : 1985-90


# **The Multicenter InSync ICD II Study ( MIRACLE ICD II )**

**Effects of Cardiac Resynchronization on  
Disease Progression in Patients with Left  
Ventricular Systolic Dysfunction, an Indication  
for an Implantable Cardioverter-Defibrillator  
and Mildly Symptomatic Chronic Heart Failure**


# ENROLLMENT AND FOLLOW-UP



# ENROLLMENT AND FOLLOW-UP




# STUDY DESIGN






# IMPROVEMENTS IN CARDIAC VOLUMES AND DIMENSIONS




# EFFECTS OF CRT ON COMPOSITE RESPONSES



# CRT EFFECTS ON VENTRICULAR ARRHYTHMIAS

During 6 Month Randomization Period




# **The REsynchronization reVERses Remodeling in Systolic left vEntricular dysfunction (REVERSE) study**

**Rationale and Design of a Randomized Controlled Trial to Assess the Safety and Efficacy of Cardiac Resynchronization Therapy in Patients with Asymptomatic Left Ventricular Dysfunction with Previous Symptoms or Mild Heart Failure**

# The REsynchronization reVERses Remodeling in Systolic left vEntricular dysfunction (REVERSE) study

<b>Patients</b>	NYHA Class I-II, QRS $\geq$ 120 ms, LVEF $\leq$ 40%, LVEDD $\geq$ 55 mm, w/o bradycardia, with or without ICD indication, on OMT
<b>Objective</b>	Assess whether CRT will limit the clinical progression of HF
<b>Primary EP</b>	Clinical Composite Response <sup>1</sup>
<b>Key Secondary</b>	Left Ventricular End Systolic Volume index
<b>Size, Locations</b>	683 patients in 115 centers in US, Europe, Canada
<b>Sponsor</b>	Medtronic

# The REsynchronization reVERses Remodeling in Systolic left vEntricular dysfunction (REVERSE) study



# MADIT-CRT: Automatic Defibrillator Implantation With Cardiac Resynchronization Therapy

## PURPOSE

The MADIT-CRT trial is designed to determine if combined ICD - CRT-D will reduce the risk of mortality and heart failure (HF) events by approximately 25%, in subjects who are in NYHA Class II with non-ischemic or ischemic cardiopathy and subjects who are in NYHA Class I with ischemic cardiopathy, left ventricular dysfunction (LVEF  $\leq$  0.30), and QRS duration  $\geq$  130 ms.

# MADIT-CRT

<b>Patients</b>	NYHA Class I / II, QRS $\geq$ 130 ms, LVEF $\leq$ 30%, post MI > 3 months or dilated cardiomyopathy with or without non-sustained VT, on optimal medical therapy (OMT)
<b>Objective</b>	Evaluate effect of CRT on the clinical progression of heart failure
<b>Primary EP</b>	Reduction in all-cause mortality + heart failure event
<b>Key Secondary</b>	Left-ventricular end-systolic volume index
<b>Size, Locations</b>	1,820 patients in multiple centers in US
<b>Sponsor</b>	Guidant



# **MADIT-CRT: Automatic Defibrillator Implantation With Cardiac Resynchronization Therapy**

## **PRIMARY OUTCOMES**

**To determine whether CRT-D in high-risk coronary subjects will significantly reduce the combined endpoint of all-cause mortality or HF events when compared to ICD-only therapy, whichever comes first**

# **MADIT-CRT: Automatic Defibrillator Implantation With Cardiac Resynchronization Therapy**

## **SECONDARY OUTCOMES**

**Evaluate the effects of CRT-D, relative to ICD-only, on the changes from baseline to one year on echocardiogram (ECHO)-determined left ventricular internal volume at end systole with CRT turned off during the one year echocardiogram;**

# **MADIT-CRT: Automatic Defibrillator Implantation With Cardiac Resynchronization Therapy**

## **SECONDARY OUTCOMES**


**Evaluate the effects of CRT-D, relative to ICD-only, on the changes from baseline to one year on ECHO-determined left ventricular internal volume at end diastole with CRT turned off during the one year echocardiogram;**

# **MADIT-CRT: Automatic Defibrillator Implantation With Cardiac Resynchronization Therapy**

## **SECONDARY OUTCOMES**

**Evaluate the effects of CRT-D, relative to ICD-only, on the subject-specific rates of multiple HF events over the full study period**

# MADIT-CRT



# IN CONCLUSION ...

# A DEFIBRILLATOR IS INDICATED : SHOULD WE RESYNCHRONISE ?

...